Abstract
Introduction Breast cancer is the second leading cause of cancer-related death in women. Breast cancer affects women of all ages, races, ethnicities, socioeconomic strata, and geographic locales. Once breast cancer is diagnosed, the tumor stage has to be accurately determined before therapy is chosen and the prognosis known. Aim Whole-body 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography–computed tomography (PET/CT) improves staging of patients with breast cancer and significantly changes the therapeutic management of these patients. Patients and methods This study was carried out in Cairo Scan Radiology Center from March 2018 to September 2018 for 34 female patients. The age ranged from 37 to 79 years, and the mean age was 56 years. All data were acquired with a combined PET/CT in-line system. Results Combined 18-FDG PET/CT provides the ability to combine functional and morphologic information in a single study. So, combined PET/CT sensitivity was 98.11% compared with 81.7% for CT alone, with P value of combined PET/CT compared with CT alone being 0.002. Conclusion Combined 18-FDG PET/CT provides the ability to combine functional and morphologic information in a single study, thus becoming a powerful imaging modality for diagnosis and staging of breast cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Scientific Journal of Al-Azhar Medical Faculty, Girls
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
